Logo image of AJ91.DE

DOCCHECK AG (AJ91.DE) Stock Fundamental Analysis

FRA:AJ91 - Deutsche Boerse Ag - DE000A1A6WE6 - Common Stock - Currency: EUR

12.5  0 (0%)

Fundamental Rating

6

Taking everything into account, AJ91 scores 6 out of 10 in our fundamental rating. AJ91 was compared to 11 industry peers in the Health Care Technology industry. AJ91 is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. AJ91 is not valued too expensively and it also shows a decent growth rate. Finally AJ91 also has an excellent dividend rating. These ratings would make AJ91 suitable for dividend investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year AJ91 was profitable.
In the past year AJ91 had a positive cash flow from operations.
In the past 5 years AJ91 has always been profitable.
Each year in the past 5 years AJ91 had a positive operating cash flow.
AJ91.DE Yearly Net Income VS EBIT VS OCF VS FCFAJ91.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M

1.2 Ratios

AJ91 has a Return On Assets of 9.09%. This is in the better half of the industry: AJ91 outperforms 63.64% of its industry peers.
AJ91's Return On Equity of 13.18% is fine compared to the rest of the industry. AJ91 outperforms 63.64% of its industry peers.
The Return On Invested Capital of AJ91 (8.86%) is better than 72.73% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AJ91 is in line with the industry average of 9.32%.
Industry RankSector Rank
ROA 9.09%
ROE 13.18%
ROIC 8.86%
ROA(3y)7.87%
ROA(5y)12.82%
ROE(3y)11.84%
ROE(5y)19.17%
ROIC(3y)9.31%
ROIC(5y)15.17%
AJ91.DE Yearly ROA, ROE, ROICAJ91.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

With a Profit Margin value of 9.82%, AJ91 perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
In the last couple of years the Profit Margin of AJ91 has remained more or less at the same level.
The Operating Margin of AJ91 (12.33%) is better than 63.64% of its industry peers.
In the last couple of years the Operating Margin of AJ91 has declined.
AJ91 has a better Gross Margin (79.18%) than 63.64% of its industry peers.
AJ91's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 12.33%
PM (TTM) 9.82%
GM 79.18%
OM growth 3Y-13.6%
OM growth 5Y-2.73%
PM growth 3Y-9.54%
PM growth 5Y0.26%
GM growth 3Y11.03%
GM growth 5Y-0.26%
AJ91.DE Yearly Profit, Operating, Gross MarginsAJ91.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AJ91 is creating some value.
The number of shares outstanding for AJ91 remains at a similar level compared to 1 year ago.
Compared to 5 years ago, AJ91 has more shares outstanding
The debt/assets ratio for AJ91 has been reduced compared to a year ago.
AJ91.DE Yearly Shares OutstandingAJ91.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
AJ91.DE Yearly Total Debt VS Total AssetsAJ91.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

AJ91 has an Altman-Z score of 4.42. This indicates that AJ91 is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.42, AJ91 is doing good in the industry, outperforming 72.73% of the companies in the same industry.
There is no outstanding debt for AJ91. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.42
ROIC/WACC1.29
WACC6.87%
AJ91.DE Yearly LT Debt VS Equity VS FCFAJ91.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 2.74 indicates that AJ91 has no problem at all paying its short term obligations.
The Current ratio of AJ91 (2.74) is better than 90.91% of its industry peers.
AJ91 has a Quick Ratio of 2.50. This indicates that AJ91 is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.50, AJ91 belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.74
Quick Ratio 2.5
AJ91.DE Yearly Current Assets VS Current LiabilitesAJ91.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

AJ91 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 133.18%, which is quite impressive.
Measured over the past years, AJ91 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.57% on average per year.
Looking at the last year, AJ91 shows a small growth in Revenue. The Revenue has grown by 0.69% in the last year.
The Revenue has been growing by 10.68% on average over the past years. This is quite good.
EPS 1Y (TTM)133.18%
EPS 3Y-22.65%
EPS 5Y10.57%
EPS Q2Q%501.79%
Revenue 1Y (TTM)0.69%
Revenue growth 3Y-14.46%
Revenue growth 5Y10.68%
Sales Q2Q%7.91%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AJ91.DE Yearly Revenue VS EstimatesAJ91.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 12.02, the valuation of AJ91 can be described as correct.
AJ91's Price/Earnings ratio is rather cheap when compared to the industry. AJ91 is cheaper than 81.82% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.19, AJ91 is valued rather cheaply.
Industry RankSector Rank
PE 12.02
Fwd PE N/A
AJ91.DE Price Earnings VS Forward Price EarningsAJ91.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AJ91 is valued cheaply inside the industry as 90.91% of the companies are valued more expensively.
100.00% of the companies in the same industry are more expensive than AJ91, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 9.74
EV/EBITDA 4
AJ91.DE Per share dataAJ91.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

AJ91 has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.14
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

8

5. Dividend

5.1 Amount

AJ91 has a Yearly Dividend Yield of 6.00%, which is a nice return.
AJ91's Dividend Yield is rather good when compared to the industry average which is at 3.73. AJ91 pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.35, AJ91 pays a better dividend.
Industry RankSector Rank
Dividend Yield 6%

5.2 History

The dividend of AJ91 has a limited annual growth rate of 4.52%.
Dividend Growth(5Y)4.52%
Div Incr Years1
Div Non Decr Years1
AJ91.DE Yearly Dividends per shareAJ91.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

48.02% of the earnings are spent on dividend by AJ91. This is a bit on the high side, but may be sustainable.
AJ91's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP48.02%
EPS Next 2YN/A
EPS Next 3YN/A
AJ91.DE Yearly Income VS Free CF VS DividendAJ91.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M 4M 6M 8M 10M
AJ91.DE Dividend Payout.AJ91.DE Dividend Payout, showing the Payout Ratio.AJ91.DE Dividend Payout.PayoutRetained Earnings

More info and screens

DOCCHECK AG

FRA:AJ91 (7/14/2025, 7:00:00 PM)

12.5

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)09-20 2024-09-20
Earnings (Next)N/A N/A
Inst Owners8.86%
Inst Owner ChangeN/A
Ins Owners71.92%
Ins Owner ChangeN/A
Market Cap63.38M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6%
Yearly Dividend0.5
Dividend Growth(5Y)4.52%
DP48.02%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 12.02
Fwd PE N/A
P/S 1.18
P/FCF 9.74
P/OCF 8.29
P/B 1.58
P/tB 1.59
EV/EBITDA 4
EPS(TTM)1.04
EY8.32%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.28
FCFY10.27%
OCF(TTM)1.51
OCFY12.06%
SpS10.61
BVpS7.91
TBVpS7.87
PEG (NY)N/A
PEG (5Y)1.14
Profitability
Industry RankSector Rank
ROA 9.09%
ROE 13.18%
ROCE 14.96%
ROIC 8.86%
ROICexc 17.58%
ROICexgc 17.72%
OM 12.33%
PM (TTM) 9.82%
GM 79.18%
FCFM 12.1%
ROA(3y)7.87%
ROA(5y)12.82%
ROE(3y)11.84%
ROE(5y)19.17%
ROIC(3y)9.31%
ROIC(5y)15.17%
ROICexc(3y)16.17%
ROICexc(5y)32.75%
ROICexgc(3y)16.36%
ROICexgc(5y)34.31%
ROCE(3y)15.72%
ROCE(5y)25.61%
ROICexcg growth 3Y-26.82%
ROICexcg growth 5Y-2.82%
ROICexc growth 3Y-26.26%
ROICexc growth 5Y-1.57%
OM growth 3Y-13.6%
OM growth 5Y-2.73%
PM growth 3Y-9.54%
PM growth 5Y0.26%
GM growth 3Y11.03%
GM growth 5Y-0.26%
F-Score6
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 45.88%
Cap/Sales 2.11%
Interest Coverage 250
Cash Conversion 83.94%
Profit Quality 123.15%
Current Ratio 2.74
Quick Ratio 2.5
Altman-Z 4.42
F-Score6
WACC6.87%
ROIC/WACC1.29
Cap/Depr(3y)102.11%
Cap/Depr(5y)131.26%
Cap/Sales(3y)5.41%
Cap/Sales(5y)5.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)133.18%
EPS 3Y-22.65%
EPS 5Y10.57%
EPS Q2Q%501.79%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.69%
Revenue growth 3Y-14.46%
Revenue growth 5Y10.68%
Sales Q2Q%7.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y86.96%
EBIT growth 3Y-26.09%
EBIT growth 5Y7.66%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.74%
FCF growth 3Y-1.99%
FCF growth 5Y54.46%
OCF growth 1Y1.69%
OCF growth 3Y-11.25%
OCF growth 5Y33.53%